<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657605</url>
  </required_header>
  <id_info>
    <org_study_id>20060282</org_study_id>
    <secondary_id>1ROIDK58851-01</secondary_id>
    <nct_id>NCT00657605</nct_id>
  </id_info>
  <brief_title>Effects of Human Leptin Replacement</brief_title>
  <official_title>Effects of Human Leptin Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that leptin contributes to the regulation of the dynamics
      of human endocrine function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three separate, but complementary, specific aims, will elucidate the role of leptin in the
      regulation of (A) the human pituitary-adrenal axis, (B) the human pituitary-gonadal axis, and
      (C) the human pituitary-thyroid axis. These aims will be approached by a carefully designed,
      prospective clinical study of the rapidly-sampled dynamics of endocrine rhythms during the
      course of leptin-replacement treatment in the only three adult individuals identified in the
      world so far who are leptin-naive due to a functional leptin gene mutation. A study of
      leptin-naive subjects avoids all confounding factors and pitfalls, because the only bioactive
      leptin to which they will be exposed is the exogenously administered recombinant protein.
      Thus, this proposal will permit us to ascertain the endocrine effects of human leptin. The
      proposed studies will elucidate key aspects of human endocrine function and will give new
      insights on the role of leptin in human endocrine regulation.

      We also propose to perform structural MRI scans (on and off leptin replacement) to test the
      association of the changes in brain tissue composition with leptin replacement, and to test
      how leptin influences regional brain function during the presentation of food-related stimuli
      (pictures of food), which we will present to the patients along with neutral pictures (e.g.,
      landscapes). We will test how this possible effect on brain function will be related to food
      craving or hunger.

      In yet another part of the study we will assess the kinetics of human recombinant leptin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2001</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight loss</measure>
    <time_frame>Before and every 6 months after treatment is initiated, from 2001 to 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of metabolic parameters</measure>
    <time_frame>Before and every 6 months after treatment is initiated, from 2001 to 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three adult patients with congenital leptin deficiency.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant methionyl human leptin</intervention_name>
    <description>Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Metreleptin</other_name>
    <other_name>r-metHuLeptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Congenital leptin deficiency (these are only 3 adult individuals in the world that
             have been identified as leptin-na√Øve thus far).

        Exclusion Criteria:

          -  Pregnant, trying to become pregnant, breast-feeding an infant or sexually active
             women, not using contraception.

          -  Subjects with hemoglobin levels below 12 g/dl.

          -  Subjects whose body contains a ferromagnetic implanted device that might produce a
             safety hazard during fMRI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Licinio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine, Center on Pharmacogenomics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998 Mar;18(3):213-5.</citation>
    <PMID>9500540</PMID>
  </reference>
  <results_reference>
    <citation>Baicy K, London ED, Monterosso J, Wong ML, Delibasi T, Sharma A, Licinio J. Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18276-9. Epub 2007 Nov 6.</citation>
    <PMID>17986612</PMID>
  </results_reference>
  <results_reference>
    <citation>Licinio J, Ribeiro L, Busnello JV, Delibasi T, Thakur S, Elashoff RM, Sharma A, Jardack PM, Depaoli AM, Wong ML. Effects of leptin replacement on macro- and micronutrient preferences. Int J Obes (Lond). 2007 Dec;31(12):1859-63. Epub 2007 Aug 7.</citation>
    <PMID>17684509</PMID>
  </results_reference>
  <results_reference>
    <citation>Licinio J, Milane M, Thakur S, Whelan F, Yildiz BO, Delibasi T, de Miranda PB, Ozata M, Bolu E, Depaoli A, Wong ML. Effects of leptin on intake of specific micro- and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. Appetite. 2007 Nov;49(3):594-9. Epub 2007 Apr 6.</citation>
    <PMID>17517446</PMID>
  </results_reference>
  <results_reference>
    <citation>Williamson DA, Ravussin E, Wong ML, Wagner A, Dipaoli A, Caglayan S, Ozata M, Martin C, Walden H, Arnett C, Licinio J. Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite. 2005 Aug;45(1):75-80.</citation>
    <PMID>15949871</PMID>
  </results_reference>
  <results_reference>
    <citation>Matochik JA, London ED, Yildiz BO, Ozata M, Caglayan S, DePaoli AM, Wong ML, Licinio J. Effect of leptin replacement on brain structure in genetically leptin-deficient adults. J Clin Endocrinol Metab. 2005 May;90(5):2851-4. Epub 2005 Feb 15.</citation>
    <PMID>15713712</PMID>
  </results_reference>
  <results_reference>
    <citation>Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM, Wong ML. Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6. Epub 2004 Mar 9.</citation>
    <PMID>15070752</PMID>
  </results_reference>
  <results_reference>
    <citation>Mantzoros CS, Ozata M, Negrao AB, Suchard MA, Ziotopoulou M, Caglayan S, Elashoff RM, Cogswell RJ, Negro P, Liberty V, Wong ML, Veldhuis J, Ozdemir IC, Gold PW, Flier JS, Licinio J. Synchronicity of frequently sampled thyrotropin (TSH) and leptin concentrations in healthy adults and leptin-deficient subjects: evidence for possible partial TSH regulation by leptin in humans. J Clin Endocrinol Metab. 2001 Jul;86(7):3284-91.</citation>
    <PMID>11443202</PMID>
  </results_reference>
  <results_reference>
    <citation>Ozata M, Ozdemir IC, Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab. 1999 Oct;84(10):3686-95. Erratum in: J Clin Endocrinol Metab 2000 Jan;85(1):416.</citation>
    <PMID>10523015</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>April 14, 2008</last_update_submitted>
  <last_update_submitted_qc>April 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Julio Licinio. MD</name_title>
    <organization>University of Miami</organization>
  </responsible_party>
  <keyword>Congenital leptin deficiency</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

